Evidence map›Paper›PMID 40972884›Full record

ArticleExperimental cell research2025

Co-delivery of ripasudil and dexamethasone in trabecular meshwork cells for potential prevention of GC-induced ocular hypertension.

Tilahun Ayane Debele, Yong Yuan, Winston Kao, Chia-Yang Liu, Eskezeia Y Dessie, Yoonjee C Park

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental cell research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tilahun Ayane DebeleDepartment of Chemical & Environmental Engineering, College of Engineering and Applied Science (CEAS), University of Cincinnati, Cincinnati, 45221, OH, USA.
Yong YuanDepartment of Ophthalmology, College of Medicine, University of Cincinnati, 45267, OH, USA.
Winston KaoDepartment of Ophthalmology, College of Medicine, University of Cincinnati, 45267, OH, USA.
Chia-Yang LiuDepartment of Ophthalmology, College of Medicine, University of Cincinnati, 45267, OH, USA.
Eskezeia Y DessieDivision of Asthma Research, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, 45229, OH, USA.
Yoonjee C ParkDepartment of Chemical & Environmental Engineering, College of Engineering and Applied Science (CEAS), University of Cincinnati, Cincinnati, 45221, OH, USA; Department of Ophthalmology, College of Medicine, University of Cincinnati, 45267, OH, USA; Department of Biomedical Engineering, College of Engineering and Applied Science (CEAS), University of Cincinnati, Cincinnati, 45221, OH, USA. Electronic address: Yoonjee.park@uc.edu.

Funding

Undergraduate Research for Dose-Controllable Drug Delivery ImplantsR15EY031500 · NEI · UNIVERSITY OF CINCINNATI · PI PARK, YOONJEE · 2021 to 2021
$475k
Co-Delivery Dose-Controllable Implants for Advanced Chronic Eye Disease TreatmentR03TR004429 · NCATS · UNIVERSITY OF CINCINNATI · PI PARK, YOONJEE · 2023 to 2024
$160k
NCATS NIH HHS R03 TR004429NEI NIH HHS R15 EY031500
6 · The paper itself

Abstract

The purpose of this in vitro study is to investigate whether the co-delivery of Ripasudil (Rip) can suppress the expression of genes related to glaucoma pathogenesis induced by prolonged dexamethasone (Dex) use, which can lead to ocular hypertension and potentially glaucoma formation. The effects of Rip (10 μM) on Dex (100 nM)-treated human trabecular meshwork (TM) cells were tested through co-delivery and sequential treatments using RNA-seq. Genome-wide analysis was performed using gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis with Enrichr and DAVID gene analysis tools. Gene enrichment and pathway analysis revealed that Rip, when co-delivered or sequentially delivered with Dex, influenced genes involved in glaucoma-related pathways such as focal adhesion, extracellular matrix (ECM) organization, and regulation of the actin cytoskeleton. Rip treatment downregulated genes like ACTA2, COL11A1, ECM2, MBP, and ANGPTL7, which are associated with increased outflow resistance and elevated intraocular pressure (IOP). Additionally, Rip upregulated ITGA11, a gene that promotes actin cytoskeleton reorganization and TM cell relaxation by inhibiting the Rho-ROCK pathway. Overall, co-delivery or sequential delivery of Rip can reverse or prevent Dex-induced ocular hypertension and glaucoma formation by modulating the expression of glaucoma-related genes at the transcriptional level.

Indexed as

DexamethasoneIsoquinolinesOcular HypertensionSulfonamidesTrabecular MeshworkCells, CulturedGene Expression RegulationGlaucomaGlucocorticoidsHumansIntraocular Pressurerho-Associated KinasesDexamethasoneGlucocorticoidsIsoquinolinesK-115rho-Associated KinasesSulfonamidesDexamethasoneGlaucomaHuman trabecular meshwork cellsRipasudilRNA-Seq

Identifiers

PMID40972884
PMCPMC12665209

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.